Jennifer Harthan
Optometrist · Chicago, ILNPI 1801818026
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $51,345 of the $84,178 with a category attached, or 61.0%. Alcon accounts for 76.6% of it on its own, with 21 other manufacturers making up the rest. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $475.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$65K
- Johnson & Johnson Vision Care, Inc.$7K
- Coopervision Inc.$4K
- Ocular Therapeutix, Inc.$2K
- AbbVie$1K
- Novartis$1K
- plus $4K from 16 others
Across 36 payments — averaging $6869.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$72K
- Bausch Health US, LLC$62K
- Ocular Therapeutix, Inc.$50K
- Kala Pharmaceuticals, Inc.$39K
- Bausch & Lomb Americas Inc.$25K
What the payments were for
- Consulting fees$51,34561%
- Speaking & faculty fees$15,71819%
- Travel & lodging$10,06012%
- Food & beverage$6,2547%
- Gifts$8011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 70 | $64,514 |
| Johnson & Johnson Vision Care, Inc. | 22 | $7,077 |
| Coopervision Inc. | 22 | $3,581 |
| Ocular Therapeutix, Inc. | 4 | $2,370 |
| AbbVie(2 entities) | 8 | $1,413 |
| Novartis | 15 | $1,214 |
| Tarsus Pharmaceuticals, Inc. | 6 | $990 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $813 |
| Visionary Optics LLC | 2 | $801 |
| Kala Pharmaceuticals, Inc. | 1 | $700 |
| Bausch & Lomb Americas Inc. | 7 | $126 |
| Shire North American Group Inc | 3 | $124 |
| Glaukos Corporation | 2 | $104 |
| Harrow Eye, LLC | 1 | $100 |
| Sanofi | 1 | $46 |
| ABB Con-cise Optical Group LLC | 1 | $41 |
| Visioneering Technologies, Inc. | 1 | $35 |
| Oyster Point Pharma, Inc. | 2 | $34 |
| Carl Zeiss Meditec, Inc. | 1 | $33 |
| Dompe US, Inc. | 1 | $28 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES TOTAL1$41,416
- TOTAL30$41,416
- Precision 1$35,284
- Precision7$16,170
- Precision 7$12,465
- Acuvue$6,698
- MiSight Contact Lens$2,715
- DEXTENZA$2,280
- XIIDRA$1,067
- LUMIGAN$781
- BIOTRUE$750
- ULTRA$750
- EYSUVIS$700
- ALPHAGAN P$650
- COMBIGAN$650
- AcrySof$429
- Rose K Contact Lens$150
- MyDay Contact Lens$100
- VEVYE$100
How this compares
$84,178 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 55 | $44,804 |
| XiidraLifitegrast | 39 | $34,703 |
| MieboPerfluorohexyloctane/Pf | 42 | $31,665 |
| CequaCyclosporine | 13 | $13,880 |
| Cyclosporine | 25 | $5,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $126 | $66,36881 claims |
| AbbVieRestasis | $1,413 | $44,80455 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $19 | $13,88013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.
Other optometrist in Chicago
- Pamela LoweChicago$447K
- Michael ChaglasianChicago$367K
- Jessilin QuintChicago$366K
- Jullian CerasuoloChicago$329K
- Neil HodurChicago$67K
- James SementilliChicago$25K
- Lindsay SicksChicago$23K
- Emma LoyfmanChicago$23K
- Michelle ManChicago$20K
- Vincent BrandysChicago$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.